Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes
Executive Summary
ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.
You may also be interested in...
Biogen Vumerity Receives Full US Approval, But GI Comparison With Tecfidera Must Wait
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates
Immuno-oncology R&D based around an interleukin-2 agonist in early clinical studies has attracted attention to Alkermes, but the CNS disorders specialty company is also concentrating on a new mechanism-of-action antidepressant that is nearing the market, and a new antipsychotic.
Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.